Oral orciprenaline in the treatment of chronic asthma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D009921:Metaproterenol / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010627:Phenethylamines / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D012118:Resorcinols / Q000627:therapeutic use*; D012119:Respiration / Q000187:drug effects; D013607:Tablets; D008258:Waldenstrom Macroglobulinemia / Q000150:complications
D001993:Bronchodilator Agents; D010627:Phenethylamines; D012118:Resorcinols; D013607:Tablets; D009921:Metaproterenol; D011241:Prednisone